Nasdaq

Teva Pharmaceutical Industries Presents Final Analysis of PEARL Study Demonstrating Sustained Effectiveness of AJOVY in Migraine Prevention at EAN 2025 Congress

Teva Pharmaceutical Industries Ltd. announced the final analysis of the PEARL Phase 4 study at the European Academy of Neurology Congress 2025, confirming that AJOVY (fremanezumab) is effective in ...
ascopubs.org

Final analysis of a multicenter, open-label, phase 2 study evaluating the efficacy and safety of tislelizumab (TIS) in combination with fruquintinib (F) in patients (pts) with ...

Impact of body mass index on immunotherapy outcomes and complications in solid tumor patients: A real-world evidence analysis. Median progression-free survival, mo (95% CI) 4.6 (3.4, 7.4) 4.6 (3.6, ...
ascopubs.org

Pembrolizumab Plus Chemotherapy Versus Chemotherapy as Perioperative Therapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer: Final Analysis of the Randomized ...

Arsenic Trioxide and All-Trans Retinoic Acid Combination Therapy for the Treatment of High-Risk Acute Promyelocytic Leukemia: Results From the APOLLO Trial We report results of the final analysis of ...
The New England Journal of Medicine

Improved Survival with Enzalutamide in Biochemically Recurrent Prostate Cancer

In the phase 3 EMBARK trial, enzalutamide plus leuprolide and enzalutamide monotherapy were associated with longer metastasis-free survival than leuprolide alone among patients with biochemically ...
Nature

Final Analysis of a Study of Etranacogene Dezaparvovec for Hemophilia B

The Nature Index 2025 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...